Moxifloxacin prophylaxis in neutropenic patients | Zendy

Heike von Baum | Zendy; Anja Sigge | Zendy; Martin Bommer | Zendy; Winfried V. Kern | Zendy; R. Marre | Zendy; Hartmut Döhner | Zendy; P. Kern | Zendy; Stefan Reuter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Moxifloxacin prophylaxis in neutropenic patients

Author(s) -

Heike von Baum,

Anja Sigge,

Martin Bommer,

Winfried V. Kern,

R. Marre,

Hartmut Döhner,

P. Kern,

Stefan Reuter

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl320

Subject(s) - moxifloxacin , levofloxacin , medicine , neutropenia , incidence (geometry) , observational study , antibiotics , bacteremia , intensive care medicine , chemotherapy , microbiology and biotechnology , biology , physics , optics

Recent studies have shown a beneficial impact of fluoroquinolones on infection-related morbidity and mortality for patients with haematological malignancies during neutropenia. Among the fluoroquinolones moxifloxacin currently provides one of the broadest spectra of antibacterial activity and may be suitable for prophylaxis during neutropenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research